Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The companyâs patented DPPÂŽ technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembioâs extensive scientific expertise, its novel DPPÂŽ technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembioâs products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Source
No articles found.
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...
Collegium Pharmaceutical is a specialty pharmac...
InSitu Biologics is an emerging biotech company focusing on development of AnestaG...
InSitu Biologics is an emerging biotech company...
Biomerica, Inc. is a global biomedical company that develops, manufactures and mar...
Biomerica, Inc. is a global biomedical company ...
We are a global medical technology company that develops, manufactures, and market...
We are a global medical technology company that...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.